Andra AP fonden Sells 22,100 Shares of Humana Inc. (NYSE:HUM)

Andra AP fonden cut its stake in Humana Inc. (NYSE:HUM - Free Report) by 59.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,200 shares of the insurance provider's stock after selling 22,100 shares during the quarter. Andra AP fonden's holdings in Humana were worth $3,856,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of HUM. FPC Investment Advisory Inc. purchased a new stake in shares of Humana during the 4th quarter worth about $27,000. Centricity Wealth Management LLC acquired a new position in Humana in the fourth quarter worth approximately $30,000. Ashton Thomas Securities LLC bought a new position in Humana during the third quarter valued at approximately $31,000. Atwood & Palmer Inc. lifted its stake in Humana by 64.5% in the fourth quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after acquiring an additional 60 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new stake in Humana in the fourth quarter valued at approximately $49,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of NYSE HUM traded down $1.04 during trading hours on Tuesday, reaching $250.21. The stock had a trading volume of 1,387,813 shares, compared to its average volume of 1,676,635. The company has a market cap of $30.19 billion, a price-to-earnings ratio of 25.15, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The business's fifty day moving average is $271.67 and its two-hundred day moving average is $281.65. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Remove Ads

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.41%. Humana's payout ratio is presently 35.58%.

Insider Buying and Selling

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.32% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Cantor Fitzgerald restated a "neutral" rating and set a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. Barclays boosted their price target on Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. StockNews.com lowered Humana from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. Finally, Truist Financial boosted their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Twenty analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.